Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$1.48 -1.7%	$1.35	$0.87 ▼ $6.78	$150.99M	0.74	839,031 shs	233,289 shs
DNLI Denali Therapeutics	$14.70 -1.4%	$14.42	$10.57 ▼ $33.33	$2.13B	1.33	1.14 million shs	613,309 shs
FATE Fate Therapeutics	$1.15 +2.2%	$1.21	$0.66 ▼ $5.92	$128.36M	2.18	2.23 million shs	1.21 million shs
RGNX REGENXBIO	$8.73 +1.3%	$8.99	$5.04 ▼ $15.36	$438.40M	1.06	930,242 shs	423,944 shs
RVMD Revolution Medicines	$37.00 -0.5%	$39.54	$29.17 ▼ $62.40	$7.05B	1.06	1.68 million shs	1.11 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	-0.34%	-4.84%	+44.61%	-66.55%
DNLI Denali Therapeutics	0.00%	+4.22%	+1.91%	+24.75%	-31.01%
FATE Fate Therapeutics	0.00%	+10.10%	-19.37%	+52.08%	-63.77%
RGNX REGENXBIO	0.00%	+4.05%	-13.39%	+38.79%	-19.32%
RVMD Revolution Medicines	0.00%	+0.24%	-8.37%	+18.14%	+0.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALEC Alector	3.7452 of 5 stars	3.1	3.0	4.5	0.6	2.5	0.0
DNLI Denali Therapeutics	4.6394 of 5 stars	4.5	2.0	4.7	2.9	2.5	0.0
FATE Fate Therapeutics	4.1888 of 5 stars	3.1	3.0	4.7	2.5	1.7	0.6
RGNX REGENXBIO	4.5312 of 5 stars	3.4	3.0	4.6	2.3	3.3	0.6
RVMD Revolution Medicines	4.5785 of 5 stars	4.5	2.0	4.7	3.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.14	Hold	$4.00	171.19% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.71	129.43% Upside
FATE Fate Therapeutics	2.13	Hold	$3.83	234.79% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	262.26% Upside
RVMD Revolution Medicines	3.00	Buy	$67.58	82.66% Upside

Current Analyst Ratings Breakdown

Latest DNLI, ALEC, FATE, RVMD, and RGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/24/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00 ➝ $73.00
6/24/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/14/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $72.00
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/9/2025	ALEC Alector	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$100.56M	1.47	N/A	N/A	$1.29 per share	1.14
DNLI Denali Therapeutics	$330.53M	6.46	N/A	N/A	$8.53 per share	1.72
FATE Fate Therapeutics	$13.34M	9.84	N/A	N/A	$2.80 per share	0.41
RGNX REGENXBIO	$83.33M	5.25	N/A	N/A	$5.24 per share	1.67
RVMD Revolution Medicines	$11.58M	595.16	N/A	N/A	$13.47 per share	2.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$119.05M	-$1.26	N/A	N/A	N/A	-139.74%	-100.58%	-25.15%	8/6/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.11	N/A	N/A	N/A	-100.62%	-53.29%	-30.84%	8/7/2025 (Estimated)
RVMD Revolution Medicines	-$600.09M	-$4.00	N/A	N/A	N/A	N/A	-37.06%	-32.84%	8/6/2025 (Estimated)

Latest DNLI, ALEC, FATE, RVMD, and RGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.10	3.34	3.34
DNLI Denali Therapeutics	N/A	9.56	9.56
FATE Fate Therapeutics	N/A	8.81	8.81
RGNX REGENXBIO	N/A	2.93	2.93
RVMD Revolution Medicines	N/A	13.46	13.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
DNLI Denali Therapeutics	92.92%
FATE Fate Therapeutics	97.54%
RGNX REGENXBIO	88.08%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ALEC Alector	9.10%
DNLI Denali Therapeutics	12.50%
FATE Fate Therapeutics	5.51%
RGNX REGENXBIO	12.79%
RVMD Revolution Medicines	8.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	99.99 million	90.89 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.75 million	Optionable
RVMD Revolution Medicines	250	186.27 million	170.99 million	Optionable

DNLI, ALEC, FATE, RVMD, and RGNX Headlines

Recent News About These Companies

Leerink Partnrs Issues Positive Estimate for RVMD Earnings

July 4 at 2:35 AM | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Position Boosted by WCM Investment Management LLC

July 3 at 5:38 AM | marketbeat.com

Revolution Medicines and Summit Therapeutics Announce Clinical Collaboration to Evaluate RAS (ON) Inhibitors in Combination with Ivonescimab for Solid Tumors - Nasdaq

July 2 at 11:21 AM | nasdaq.com

Leerink Partnrs Issues Optimistic Estimate for RVMD Earnings

July 2 at 7:41 AM | marketbeat.com

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

June 30, 2025 | globenewswire.com

Lunate Capital Ltd Invests $77.66 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)

June 29, 2025 | marketbeat.com

Brokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Target Price at $67.58

June 29, 2025 | americanbankingnews.com

Q3 EPS Estimate for Revolution Medicines Raised by Analyst

June 27, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Earns "Buy" Rating from Guggenheim

June 26, 2025 | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Buy" by Analysts

June 26, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Earns "Buy" Rating from Needham & Company LLC

June 26, 2025 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Given Outperform Rating at Wedbush

June 26, 2025 | americanbankingnews.com

Revolution Medicines' (RVMD) Buy Rating Reiterated at Guggenheim

June 25, 2025 | marketbeat.com

Wedbush Reiterates "Outperform" Rating for Revolution Medicines (NASDAQ:RVMD)

June 24, 2025 | marketbeat.com

Revolution Medicines' Daraxonrasib Receives FDA Breakthrough Therapy Designation for Metastatic Pancreatic Ductal Adenocarcinoma | Nasdaq

June 24, 2025 | nasdaq.com

Needham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)

June 24, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Shares Gap Down - Here's What Happened

June 24, 2025 | marketbeat.com

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

June 24, 2025 | reuters.com

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

June 24, 2025 | globenewswire.com

Revolution Medicines, Inc.: Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS ...

June 23, 2025 | finanznachrichten.de

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

June 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock
By Leo Miller | June 9, 2025
View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock

DNLI, ALEC, FATE, RVMD, and RGNX Company Descriptions

Alector NASDAQ:ALEC

$1.48 -0.03 (-1.67%)

Closing price 07/3/2025 03:51 PM Eastern

Extended Trading

$1.48 0.00 (0.00%)

As of 07/3/2025 04:36 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics NASDAQ:DNLI

$14.70 -0.21 (-1.38%)

Closing price 07/3/2025 03:08 PM Eastern

Extended Trading

$14.69 -0.01 (-0.03%)

As of 07/3/2025 04:34 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Fate Therapeutics NASDAQ:FATE

$1.14 +0.03 (+2.23%)

Closing price 07/3/2025 02:25 PM Eastern

Extended Trading

$1.16 +0.02 (+1.75%)

As of 07/3/2025 04:26 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

REGENXBIO NASDAQ:RGNX

$8.73 +0.11 (+1.28%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$8.74 +0.00 (+0.06%)

As of 07/3/2025 04:33 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Revolution Medicines NASDAQ:RVMD

$37.00 -0.19 (-0.51%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$37.39 +0.39 (+1.05%)

As of 07/3/2025 04:56 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time